ClinicalTrials.gg
CompletedNCT02310906Updated Oct 19, 2020Results posted

Phase I/II Study of SRP-4053 in DMD Patients

A Phase 1/2 interventional study of Placebo and SRP-4053 in Duchenne Muscular Dystrophy, sponsored by Sarepta Therapeutics, Inc.. Completed at 5 sites in 4 countries. Open to male participants aged 6 Years to 15 Years. Per ClinicalTrials.gov, last updated 2020-10-19.

Sponsored by Sarepta Therapeutics, Inc. · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
39
Allocation
Randomized
Ages
6 Years to 15 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc. — 5 open to participants now, 6 under way, 2 of them phase 3. Muscular Dystrophy, Duchenne · Sarepta Therapeutics, Inc..

Enrollment
11th of 25
39 · median 24
Started
2015
with 2 others
Phase 1/2
5 of 27
none open now
Registered
6th of 27
by date

Among the 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc., this one is the 11th largest by enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2015, is one of 5 in phase 1/2, and was the 6th registered.

Muscular Dystrophy, Duchenne

482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

5 of the 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc. are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.

This study: 6 Years to 15 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc., or all of them as a file.
02

Study summary

This is a first-in-human, multiple-dose 2-part study to assess the safety, tolerability, efficacy, and pharmacokinetics of SRP-4053 in Duchenne muscular dystrophy (DMD) patients with deletions amenable to exon 53 skipping.

Read the detailed description

Part 1: Randomized, placebo-controlled dose-titration to assess safety, tolerability and pharmacokinetics of 4 dose levels of SRP-4053 in genotypically-confirmed DMD patients with deletions amenable to exon 53 skipping.

Part 2: Open-label evaluation of SRP-4053 in patients from Part 1, along with newly enrolled DMD patients with deletions amenable to exon 53 skipping and an untreated group of DMD patients with deletions not amenable to exon 53 skipping.

Safety, including adverse event monitoring and routine laboratory assessments, will be followed on an ongoing basis for all patients.

Clinical efficacy, including functional tests such as the six-minute walk test (6MWT), will be assessed at regularly scheduled study visits. Patients in the treated groups will undergo one baseline and one follow-up muscle biopsy. Patients in the untreated group will not undergo biopsies and will follow an abbreviated schedule of study assessments.

03

Conditions studied

  • Duchenne Muscular Dystrophy

Keywords

  • Duchenne muscular dystrophy
  • Exon Skipping
  • DMD
  • Exon 53
  • Ambulatory
  • Pediatric
04

Who can participate

Ages eligible
6 Years to 15 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with DMD, genotypically confirmed.
  • Intact right and left biceps muscles or an alternative upper arm muscle group.
  • Stable pulmonary and cardiac function.
  • Minimum performance on 6MWT, North Star Ambulatory Assessment, and rise (Gowers) test as specified in the study protocol.
  • On a stable dose of for at least 6 months.

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with the experimental agents BMN-195 (SMT C1100) or PRO053.
  • Current or previous treatment with any other experimental treatments within 12 weeks prior to study entry.
  • Major surgery within the last 3 months.
  • Presence of other illness.
  • Major change in physical therapy regime within the last 3 months.

Other inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    Part 1: SRP-4053

    Patients will receive SRP-4053 (golodirsen) intravenous (IV) infusions, weekly, at escalating dose levels as follows: Weeks 1-2, 4 mg/kg/week; Weeks 3-4, 10 mg/kg/week; Weeks 5-6, 20 mg/kg/week; Weeks 7-12, 30 mg/kg/week. Dosing will be interrupted or halted if specific predefined stopping criteria are met or if warranted at the discretion of the Sponsor or Investigator.

    Drug: SRP-4053

  • Placebo comparator
    Part 1: Placebo

    Patients will receive SRP-4053 placebo-matching IV infusions, weekly, for 12 weeks. Dosing will be interrupted or halted if specific predefined stopping criteria are met or if warranted at the discretion of the Sponsor or Investigator.

    Drug: Placebo

  • Experimental
    Part 2: SRP-4053

    All eligible patients from Part 1, as well as new patients, will receive SRP-4053 (golodirsen) 30 mg/kg/week IV infusions, weekly, for up to 168 weeks.

    Drug: SRP-4053

  • No intervention
    Part 2: Untreated Group

    Patients with DMD who have a genotypically confirmed deletion of exon(s) not amenable to treatment by exon 53 skipping, but who otherwise meet the same eligibility criteria as treated patients newly recruited to Part 2, will undergo the same study assessments as treated Patients (except for pharmacokinetic \[PK\] sampling and muscle biopsies), but at a reduced schedule through Week 144. The untreated patients are not considered as control group.

Interventions

  • DrugPlacebo

    SRP-4053 placebo-matching solution for IV infusion.

  • DrugGolodirsenStudies of GolodirsenGolodirsen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    SRP-4053 (golodirsen) solution for IV infusion.

06

What researchers measure

Primary outcomes

  1. Part 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs and TEAEs Leading to Discontinuation

    Adverse event (AE) was any untoward medical occurrence in a clinical trial participant, which does not necessarily have a causal relationship with the investigational drug. A Serious adverse event (SAE) was an AE resulting in any of the following outcomes: death; Life-threatening event; Required or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly. TEAEs were defined as AEs that were reported or worsened on or after the start of study drug dosing through 12 weeks. TEAEs included both Serious TEAEs and non-serious TEAEs.

    Time frame: Baseline up to Week 12

  2. Part 1: Number of Participants With Potentially Clinically Significant (PCS) Laboratory Abnormalities Reported as TEAEs

    Laboratory parameters included hematology, serum chemistry (SC), urinalysis and coagulation. Number of participants with at least one potentially clinically significant abnormal finding were reported as TEAEs. The Investigator determined whether abnormal assessment results were potentially clinically significant or not. Potentially clinical significance was defined as any variation in assessment results that had medical relevance resulting in an alteration in medical care.

    Time frame: Baseline up to Week 12

  3. Part 1: Number of Participants With Potentially Clinically Significant Abnormalities in Vital Signs Reported as TEAEs

    Vital sign parameters included systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), and body temperature. Number of participants with at least one potentially clinically significant abnormal vital signs findings were reported as TEAEs. The Investigator determined whether abnormal assessment results were potentially clinically significant or not. Potential clinical significance was defined as any variation in assessment results that had medical relevance resulting in an alteration in medical care.

    Time frame: Baseline up to Week 12

  4. Part 1: Number of Participants With Potentially Clinically Significant Abnormalities in Physical Examinations

    Physical examinations were performed by the Investigator, or qualified study staff. A full physical examination included a review of general appearance, head, eyes, ears, nose and throat, heart, lungs, abdomen, extremities, skin, lymph nodes, musculoskeletal, and neurological systems. Number of participants with potentially clinically significant abnormalities in physical examinations were reported. Potentially clinically significant abnormalities in physical examinations were based on Investigator's discretion.

    Time frame: Baseline up to Week 12

  5. Part 1: Number of Participants With Potentially Clinically Significant Abnormalities in Electrocardiogram (ECG) Reported as TEAEs

    Twelve-lead ECGs were performed at a consistent time of day throughout the study. Electrocardiograms were performed only after the participant was in the supine position, resting, and quiet for a minimum of 15 minutes. The ECG was manually reviewed and interpreted by medically qualified personnel. Number of participants with potentially clinically significant abnormalities in ECG reported as TEAEs presented here. The Investigator determined whether abnormal assessment results were potentially clinically significant or not.

    Time frame: Baseline up to Week 12

  6. Part 1: Number of Participants With Potentially Clinically Significant Abnormalities in Echocardiograms (ECHO)

    Standard, 2-dimensional ECHOs were performed at a consistent time of day throughout the study. Cardiac function events included cardiomegaly, tachycardia, and dyspnoea. The ECHO was reviewed and interpreted by medically qualified personnel. Number of participants with potentially clinically significant abnormalities in ECHO were reported.

    Time frame: Baseline up to Week 12

  7. Part 2a: Change From Baseline in the Total Distance Walked During 6-Minute Walk Test (6MWT) at Week 144 in Total Golodirsen Group

    6MWT was performed by standardized procedures for all participants. Participants were asked to walk a set course of 25 meters for 6 minutes (timed), and the distance walked (in meters) was recorded. Change from baseline in 6MWT distance at Week 144 in total golodirsen group was reported.

    Time frame: Baseline and Week 144

  8. Part 2b: Change From Baseline in the Total Distance Walked During 6-Minute Walk Test (6MWT) at Week 144 in Untreated Group (Non-exon 53 Amenable Participants)

    6MWT was performed by standardized procedures for all participants. Participants were asked to walk a set course of 25 meters for 6 minutes (timed), and the distance walked (in meters) was recorded. Change from baseline in 6MWT distance at Week 144 in untreated group (non-exon 53 amenable participants) was calculated.

    Time frame: Baseline and Week 144

  9. Part 2a: Change From Baseline in Dystrophin Protein Levels Determined by Western Blot at Week 48 in Total Golodirsen Group

    Change from baseline in dystrophin protein levels (in muscle biopsy samples) was determined by Western blot in total golodirsen group.

    Time frame: Baseline, Week 48

Secondary outcomes

  1. Part 1: Maximum Plasma Concentration (Cmax) of Golodirsen

    Maximum Concentration (Cmax) of golodirsen in plasma was evaluated.

    Time frame: Pre-dose, 5 to 10 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16 and 24 hours post-dose at Weeks 1 (for 4 mg/kg arm), 3 (for 10 mg/kg arm), 5 (for 20 mg/kg arm) and 7 (for 30 mg/kg arm)

  2. Part 1: Time to Reach Maximum Plasma Concentration (Tmax) of Golodirsen

    Time to reach maximum plasma concentration (Tmax) of golodirsen was evaluated.

    Time frame: Pre-dose, 5 to 10 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16 and 24 hours post-dose at Weeks 1 (for 4 mg/kg arm), 3 (for 10 mg/kg arm), 5 (for 20 mg/kg arm) and 7 (for 30 mg/kg arm)

  3. Part 1: Area Under the Concentration-Time Curve From Time Zero Extrapolated to the Infinity (AUCinf) of Golodirsen in Plasma

    Area under the concentration-time curve from time zero extrapolated to the infinity was evaluated.

    Time frame: Pre-dose, 5 to 10 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16 and 24 hours post-dose at Weeks 1 (for 4 mg/kg arm), 3 (for 10 mg/kg arm), 5 (for 20 mg/kg arm) and 7 (for 30 mg/kg arm)

  4. Part 1: Apparent Volume of Distribution at Steady State (Vss) of Golodirsen

    Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution at steady state of golodirsen was evaluated.

    Time frame: Pre-dose, 5 to 10 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16 and 24 hours post-dose at Weeks 1 (for 4 mg/kg arm), 3 (for 10 mg/kg arm), 5 (for 20 mg/kg arm) and 7 (for 30 mg/kg arm)

  5. Part 1: Elimination Half-life (T1/2) of Golodirsen

    T1/2 is the time measured for the plasma concentration of drug to decrease by one half. T1/2 of golodirsen was evaluated.

    Time frame: Pre-dose, 5 to 10 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16 and 24 hours post-dose at Weeks 1 (for 4 mg/kg arm), 3 (for 10 mg/kg arm), 5 (for 20 mg/kg arm) and 7 (for 30 mg/kg arm)

  6. Part 1: Total Clearance (CL) of Golodirsen

    Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

    Time frame: Pre-dose, 5 to 10 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16 and 24 hours post-dose at Weeks 1 (for 4 mg/kg arm), 3 (for 10 mg/kg arm), 5 (for 20 mg/kg arm) and 7 (for 30 mg/kg arm)

  7. Part 1: Mean Residence Time (MRT) of Golodirsen

    MRT= AUMCinf/AUCinf, where AUMCinf is the area under the first moment curve from time 0 extrapolated to infinite time, calculated using the linear/log trapezoidal method. Mean residence time of golodirsen was evaluated.

    Time frame: Pre-dose, 5 to 10 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16 and 24 hours post-dose at Weeks 1 (for 4 mg/kg arm), 3 (for 10 mg/kg arm), 5 (for 20 mg/kg arm) and 7 (for 30 mg/kg arm)

  8. Part 1: Renal Clearance (CLR) of Golodirsen

    Renal clearance was calculated using the partial AUC0-24 from the non-compartmental analysis in plasma and AE0-24. AUC0-24 was defined as area under the plasma concentration-time curve, from time 0 to 24 hours after completion of dosing. AE0-24 was defined as total cumulative amount excreted from 0 to 24 hours. Summarized data of all urine collection intervals are reported.

    Time frame: 0 to 1440 min after initiation of dosing on Day 1

  9. Part 2a: Percent Change From Baseline in Forced Vital Capacity Predicted (FVC%p) at Week144 in Total Golodirsen Group

    FVC was the total amount of air exhaled during the forced expiratory volume test that was measured during spirometry and the most important measurement of lung function. This test required participant to breath into a tube connected to a machine that measures the amount of air that can be moved in and out of the lungs after taking an inhaled bronchodilator medicine which was used to dilate participant bronchial (breathing) tubes. Percent of predicted FVC = (observed value)/ (predicted value) \* 100%.

    Time frame: Baseline, Week 144

  10. Part 2b: Percent Change From Baseline in Forced Vital Capacity Predicted (FVC%p) at Week144 in Untreated Group (Non-exon 53 Amenable Participants)

    FVC was the total amount of air exhaled during the forced expiratory volume test that was measured during spirometry and is the most important measurement of lung function. This test requires participant to breath into a tube connected to a machine that measures the amount of air that can be moved in and out of the lungs after taking an inhaled bronchodilator medicine which was used to dilate participant bronchial (breathing) tubes. Percent of predicted FVC = (observed value)/ (predicted value) \* 100%.

    Time frame: Baseline, Week 144

  11. Part 2a: Change From Baseline in Dystrophin Intensity Levels Determined by Immunohistochemistry (IHC) at Week 48 in Total Golodirsen Group

    Change from baseline in dystrophin Intensity levels (in muscle biopsy samples) was determined by Immunohistochemistry in total golodirsen group.

    Time frame: Baseline, Week 48

  12. Part 2a: Percent Change From Baseline in Exon 53 Skipping Determined by Reverse Transcription Polymerase Chain Reaction (PCR) at Week 48 in Total Golodirsen Group

    Percent change from baseline in Exon 53 skipping (in muscle biopsy samples) was determined by reverse transcription polymerase chain reaction in total golodirsen group.

    Time frame: Baseline, Week 48

  13. Part 2a: Percent Change From Baseline in Dystrophin Positive Fibers Determined by Immunohistochemistry (IHC) at Week 48 in Total Golodirsen Group

    Percent change from baseline in dystrophin positive fibers (in muscle biopsy samples) were determined by Immunohistochemistry at Week 48 in total golodirsen group.

    Time frame: Baseline, Week 48

07

Results

Posted Oct 19, 2020

Participant flow

The study was conducted at 5 sites in the France, Italy, United Kingdom and United States from 13 January 2015 to 25 March 2019.

Part 1: Double Blind Phase (12 Weeks)
Participant flow — Part 1: Double Blind Phase (12 Weeks)
MilestonePart 1: PlaceboPart 1: GolodirsenPart 2a: Total Golodirsen GroupPart 2b: Untreated Group (Natural History of Non-exon 53)
Started4800
Received 4 mg/kg0800
Received 10 mg/kg0800
Received 20 mg/kg0800
Received 30 mg/kg0800
Completed4800
Not completed0000
Part 2: Open Label Phase (168 Weeks)
Participant flow — Part 2: Open Label Phase (168 Weeks)
MilestonePart 1: PlaceboPart 1: GolodirsenPart 2a: Total Golodirsen GroupPart 2b: Untreated Group (Natural History of Non-exon 53)
Started002514
Completed00236
Not completed0028
Withdrew: Enrollment in other therapeutic study0002
Withdrew: Withdrawal by subject0024
Withdrew: Personal reasons0001
Withdrew: Lost to follow-up0001

Outcome measures

PrimaryPart 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs and TEAEs Leading to Discontinuation

Adverse event (AE) was any untoward medical occurrence in a clinical trial participant, which does not necessarily have a causal relationship with the investigational drug. A Serious adverse event (SAE) was an AE resulting in any of the following outcomes: death; Life-threatening event; Required or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly. TEAEs were defined as AEs that were reported or worsened on or after the start of study drug dosing through 12 weeks. TEAEs included both Serious TEAEs and non-serious TEAEs.

Time frame:
Baseline up to Week 12
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs and TEAEs Leading to Discontinuation
ParticipantsPart 1: PlaceboPart 1: Golodirsen (4 mg/kg)Part 1: Golodirsen (10 mg/kg)Part 1: Golodirsen (20 mg/kg)Part 1: Golodirsen (30 mg/kg)
Participants with TEAE45536
Participants with Serious TEAE00000
Participants with TEAEs leading to discontinuation00000
PrimaryPart 1: Number of Participants With Potentially Clinically Significant (PCS) Laboratory Abnormalities Reported as TEAEs

Laboratory parameters included hematology, serum chemistry (SC), urinalysis and coagulation. Number of participants with at least one potentially clinically significant abnormal finding were reported as TEAEs. The Investigator determined whether abnormal assessment results were potentially clinically significant or not. Potentially clinical significance was defined as any variation in assessment results that had medical relevance resulting in an alteration in medical care.

Time frame:
Baseline up to Week 12
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Potentially Clinically Significant (PCS) Laboratory Abnormalities Reported as TEAEs
ParticipantsPart 1: PlaceboPart 1: Golodirsen (4 mg/kg)Part 1: Golodirsen (10 mg/kg)Part 1: Golodirsen (20 mg/kg)Part 1: Golodirsen (30 mg/kg)
Hepatic Chemistry00000
Renal Chemistry00000
Hematology20100
Coagulation00000
Urinalysis00000
PrimaryPart 1: Number of Participants With Potentially Clinically Significant Abnormalities in Vital Signs Reported as TEAEs

Vital sign parameters included systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), and body temperature. Number of participants with at least one potentially clinically significant abnormal vital signs findings were reported as TEAEs. The Investigator determined whether abnormal assessment results were potentially clinically significant or not. Potential clinical significance was defined as any variation in assessment results that had medical relevance resulting in an alteration in medical care.

Time frame:
Baseline up to Week 12
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Potentially Clinically Significant Abnormalities in Vital Signs Reported as TEAEs
ParticipantsPart 1: PlaceboPart 1: Golodirsen (4 mg/kg)Part 1: Golodirsen (10 mg/kg)Part 1: Golodirsen (20 mg/kg)Part 1: Golodirsen (30 mg/kg)
Part 1: Number of Participants With Potentially Clinically Significant Abnormalities in Vital Signs Reported as TEAEs13114
PrimaryPart 1: Number of Participants With Potentially Clinically Significant Abnormalities in Physical Examinations

Physical examinations were performed by the Investigator, or qualified study staff. A full physical examination included a review of general appearance, head, eyes, ears, nose and throat, heart, lungs, abdomen, extremities, skin, lymph nodes, musculoskeletal, and neurological systems. Number of participants with potentially clinically significant abnormalities in physical examinations were reported. Potentially clinically significant abnormalities in physical examinations were based on Investigator's discretion.

Time frame:
Baseline up to Week 12
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Potentially Clinically Significant Abnormalities in Physical Examinations
ParticipantsPart 1: PlaceboPart 1: Golodirsen (4 mg/kg)Part 1: Golodirsen (10 mg/kg)Part 1: Golodirsen (20 mg/kg)Part 1: Golodirsen (30 mg/kg)
Part 1: Number of Participants With Potentially Clinically Significant Abnormalities in Physical Examinations00203
PrimaryPart 1: Number of Participants With Potentially Clinically Significant Abnormalities in Electrocardiogram (ECG) Reported as TEAEs

Twelve-lead ECGs were performed at a consistent time of day throughout the study. Electrocardiograms were performed only after the participant was in the supine position, resting, and quiet for a minimum of 15 minutes. The ECG was manually reviewed and interpreted by medically qualified personnel. Number of participants with potentially clinically significant abnormalities in ECG reported as TEAEs presented here. The Investigator determined whether abnormal assessment results were potentially clinically significant or not.

Time frame:
Baseline up to Week 12
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Potentially Clinically Significant Abnormalities in Electrocardiogram (ECG) Reported as TEAEs
ParticipantsPart 1: PlaceboPart 1: Golodirsen (4 mg/kg)Part 1: Golodirsen (10 mg/kg)Part 1: Golodirsen (20 mg/kg)Part 1: Golodirsen (30 mg/kg)
Part 1: Number of Participants With Potentially Clinically Significant Abnormalities in Electrocardiogram (ECG) Reported as TEAEs01000
PrimaryPart 1: Number of Participants With Potentially Clinically Significant Abnormalities in Echocardiograms (ECHO)

Standard, 2-dimensional ECHOs were performed at a consistent time of day throughout the study. Cardiac function events included cardiomegaly, tachycardia, and dyspnoea. The ECHO was reviewed and interpreted by medically qualified personnel. Number of participants with potentially clinically significant abnormalities in ECHO were reported.

Time frame:
Baseline up to Week 12
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Potentially Clinically Significant Abnormalities in Echocardiograms (ECHO)
ParticipantsPart 1: PlaceboPart 1: Golodirsen (4 mg/kg)Part 1: Golodirsen (10 mg/kg)Part 1: Golodirsen (20 mg/kg)Part 1: Golodirsen (30 mg/kg)
Part 1: Number of Participants With Potentially Clinically Significant Abnormalities in Echocardiograms (ECHO)00003
PrimaryPart 2a: Change From Baseline in the Total Distance Walked During 6-Minute Walk Test (6MWT) at Week 144 in Total Golodirsen Group

6MWT was performed by standardized procedures for all participants. Participants were asked to walk a set course of 25 meters for 6 minutes (timed), and the distance walked (in meters) was recorded. Change from baseline in 6MWT distance at Week 144 in total golodirsen group was reported.

Time frame:
Baseline and Week 144
Reported as:
Mean · meters
Part 2a: Change From Baseline in the Total Distance Walked During 6-Minute Walk Test (6MWT) at Week 144 in Total Golodirsen Group
metersPart 2a: Total Golodirsen Group
Part 2a: Change From Baseline in the Total Distance Walked During 6-Minute Walk Test (6MWT) at Week 144 in Total Golodirsen Group-99.0 ± 123.75
PrimaryPart 2b: Change From Baseline in the Total Distance Walked During 6-Minute Walk Test (6MWT) at Week 144 in Untreated Group (Non-exon 53 Amenable Participants)

6MWT was performed by standardized procedures for all participants. Participants were asked to walk a set course of 25 meters for 6 minutes (timed), and the distance walked (in meters) was recorded. Change from baseline in 6MWT distance at Week 144 in untreated group (non-exon 53 amenable participants) was calculated.

Time frame:
Baseline and Week 144
Reported as:
Mean · Meters
Part 2b: Change From Baseline in the Total Distance Walked During 6-Minute Walk Test (6MWT) at Week 144 in Untreated Group (Non-exon 53 Amenable Participants)
MetersPart 2b: Untreated Group (Natural History of Non-exon 53)
Part 2b: Change From Baseline in the Total Distance Walked During 6-Minute Walk Test (6MWT) at Week 144 in Untreated Group (Non-exon 53 Amenable Participants)-160.8 ± 162.41
PrimaryPart 2a: Change From Baseline in Dystrophin Protein Levels Determined by Western Blot at Week 48 in Total Golodirsen Group

Change from baseline in dystrophin protein levels (in muscle biopsy samples) was determined by Western blot in total golodirsen group.

Time frame:
Baseline, Week 48
Reported as:
Mean · Percent normal dystrophin protein level
Part 2a: Change From Baseline in Dystrophin Protein Levels Determined by Western Blot at Week 48 in Total Golodirsen Group
Percent normal dystrophin protein levelPart 2a: Total Golodirsen Group
Part 2a: Change From Baseline in Dystrophin Protein Levels Determined by Western Blot at Week 48 in Total Golodirsen Group0.924 ± 1.0129
SecondaryPart 1: Maximum Plasma Concentration (Cmax) of Golodirsen

Maximum Concentration (Cmax) of golodirsen in plasma was evaluated.

Time frame:
Pre-dose, 5 to 10 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16 and 24 hours post-dose at Weeks 1 (for 4 mg/kg arm), 3 (for 10 mg/kg arm), 5 (for 20 mg/kg arm) and 7 (for 30 mg/kg arm)
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Part 1: Maximum Plasma Concentration (Cmax) of Golodirsen
nanogram per milliliter (ng/mL)Part 1: Golodirsen (4 mg/kg)Part 1: Golodirsen (10 mg/kg)Part 1: Golodirsen (20 mg/kg)Part 1: Golodirsen (30 mg/kg)
Part 1: Maximum Plasma Concentration (Cmax) of Golodirsen7840 ± 45.717000 ± 40.939700 ± 71.853300 ± 37.9
SecondaryPart 1: Time to Reach Maximum Plasma Concentration (Tmax) of Golodirsen

Time to reach maximum plasma concentration (Tmax) of golodirsen was evaluated.

Time frame:
Pre-dose, 5 to 10 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16 and 24 hours post-dose at Weeks 1 (for 4 mg/kg arm), 3 (for 10 mg/kg arm), 5 (for 20 mg/kg arm) and 7 (for 30 mg/kg arm)
Reported as:
Median · hour
Part 1: Time to Reach Maximum Plasma Concentration (Tmax) of Golodirsen
hourPart 1: Golodirsen (4 mg/kg)Part 1: Golodirsen (10 mg/kg)Part 1: Golodirsen (20 mg/kg)Part 1: Golodirsen (30 mg/kg)
Part 1: Time to Reach Maximum Plasma Concentration (Tmax) of Golodirsen1.11 (0.77 to 1.67)1.09 (0.12 to 1.62)1.12 (0.80 to 1.58)1.12 (0.68 to 1.50)
SecondaryPart 1: Area Under the Concentration-Time Curve From Time Zero Extrapolated to the Infinity (AUCinf) of Golodirsen in Plasma

Area under the concentration-time curve from time zero extrapolated to the infinity was evaluated.

Time frame:
Pre-dose, 5 to 10 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16 and 24 hours post-dose at Weeks 1 (for 4 mg/kg arm), 3 (for 10 mg/kg arm), 5 (for 20 mg/kg arm) and 7 (for 30 mg/kg arm)
Reported as:
Geometric mean · hr*ng/mL
Part 1: Area Under the Concentration-Time Curve From Time Zero Extrapolated to the Infinity (AUCinf) of Golodirsen in Plasma
hr*ng/mLPart 1: Golodirsen (4 mg/kg)Part 1: Golodirsen (10 mg/kg)Part 1: Golodirsen (20 mg/kg)Part 1: Golodirsen (30 mg/kg)
Part 1: Area Under the Concentration-Time Curve From Time Zero Extrapolated to the Infinity (AUCinf) of Golodirsen in Plasma11800 ± 35.526400 ± 42.762300 ± 52.690800 ± 33.4
SecondaryPart 1: Apparent Volume of Distribution at Steady State (Vss) of Golodirsen

Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution at steady state of golodirsen was evaluated.

Time frame:
Pre-dose, 5 to 10 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16 and 24 hours post-dose at Weeks 1 (for 4 mg/kg arm), 3 (for 10 mg/kg arm), 5 (for 20 mg/kg arm) and 7 (for 30 mg/kg arm)
Reported as:
Geometric mean · Liter per kilogram (L/kg)
Part 1: Apparent Volume of Distribution at Steady State (Vss) of Golodirsen
Liter per kilogram (L/kg)Part 1: Golodirsen (4 mg/kg)Part 1: Golodirsen (10 mg/kg)Part 1: Golodirsen (20 mg/kg)Part 1: Golodirsen (30 mg/kg)
Part 1: Apparent Volume of Distribution at Steady State (Vss) of Golodirsen0.670 ± 38.60.767 ± 43.40.576 ± 84.50.668 ± 32.3
SecondaryPart 1: Elimination Half-life (T1/2) of Golodirsen

T1/2 is the time measured for the plasma concentration of drug to decrease by one half. T1/2 of golodirsen was evaluated.

Time frame:
Pre-dose, 5 to 10 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16 and 24 hours post-dose at Weeks 1 (for 4 mg/kg arm), 3 (for 10 mg/kg arm), 5 (for 20 mg/kg arm) and 7 (for 30 mg/kg arm)
Reported as:
Mean · hour
Part 1: Elimination Half-life (T1/2) of Golodirsen
hourPart 1: Golodirsen (4 mg/kg)Part 1: Golodirsen (10 mg/kg)Part 1: Golodirsen (20 mg/kg)Part 1: Golodirsen (30 mg/kg)
Part 1: Elimination Half-life (T1/2) of Golodirsen2.36 ± 0.5813.63 ± 2.043.27 ± 0.8973.42 ± 0.628
SecondaryPart 1: Total Clearance (CL) of Golodirsen

Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

Time frame:
Pre-dose, 5 to 10 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16 and 24 hours post-dose at Weeks 1 (for 4 mg/kg arm), 3 (for 10 mg/kg arm), 5 (for 20 mg/kg arm) and 7 (for 30 mg/kg arm)
Reported as:
Mean · Liters per hour per kilogram (L/h/kg)
Part 1: Total Clearance (CL) of Golodirsen
Liters per hour per kilogram (L/h/kg)Part 1: Golodirsen (4 mg/kg)Part 1: Golodirsen (10 mg/kg)Part 1: Golodirsen (20 mg/kg)Part 1: Golodirsen (30 mg/kg)
Part 1: Total Clearance (CL) of Golodirsen0.381 ± 36.00.405 ± 46.20.338 ± 52.20.346 ± 34.3
SecondaryPart 1: Mean Residence Time (MRT) of Golodirsen

MRT= AUMCinf/AUCinf, where AUMCinf is the area under the first moment curve from time 0 extrapolated to infinite time, calculated using the linear/log trapezoidal method. Mean residence time of golodirsen was evaluated.

Time frame:
Pre-dose, 5 to 10 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16 and 24 hours post-dose at Weeks 1 (for 4 mg/kg arm), 3 (for 10 mg/kg arm), 5 (for 20 mg/kg arm) and 7 (for 30 mg/kg arm)
Reported as:
Mean · hour
Part 1: Mean Residence Time (MRT) of Golodirsen
hourPart 1: Golodirsen (4 mg/kg)Part 1: Golodirsen (10 mg/kg)Part 1: Golodirsen (20 mg/kg)Part 1: Golodirsen (30 mg/kg)
Part 1: Mean Residence Time (MRT) of Golodirsen1.79 ± 0.3251.92 ± 0.3381.77 ± 0.4951.95 ± 0.312
SecondaryPart 1: Renal Clearance (CLR) of Golodirsen

Renal clearance was calculated using the partial AUC0-24 from the non-compartmental analysis in plasma and AE0-24. AUC0-24 was defined as area under the plasma concentration-time curve, from time 0 to 24 hours after completion of dosing. AE0-24 was defined as total cumulative amount excreted from 0 to 24 hours. Summarized data of all urine collection intervals are reported.

Time frame:
0 to 1440 min after initiation of dosing on Day 1
Reported as:
Geometric mean · L/h/kg
Part 1: Renal Clearance (CLR) of Golodirsen
L/h/kgPart 1: Golodirsen (4 mg/kg)Part 1: Golodirsen (10 mg/kg)Part 1: Golodirsen (20 mg/kg)Part 1: Golodirsen (30 mg/kg)
Part 1: Renal Clearance (CLR) of Golodirsen0.345 ± 31.90.370 ± 50.60.355 ± 42.10.374 ± 26.8
SecondaryPart 2a: Percent Change From Baseline in Forced Vital Capacity Predicted (FVC%p) at Week144 in Total Golodirsen Group

FVC was the total amount of air exhaled during the forced expiratory volume test that was measured during spirometry and the most important measurement of lung function. This test required participant to breath into a tube connected to a machine that measures the amount of air that can be moved in and out of the lungs after taking an inhaled bronchodilator medicine which was used to dilate participant bronchial (breathing) tubes. Percent of predicted FVC = (observed value)/ (predicted value) \* 100%.

Time frame:
Baseline, Week 144
Reported as:
Mean · Percent change
Part 2a: Percent Change From Baseline in Forced Vital Capacity Predicted (FVC%p) at Week144 in Total Golodirsen Group
Percent changePart 2a: Total Golodirsen Group
Part 2a: Percent Change From Baseline in Forced Vital Capacity Predicted (FVC%p) at Week144 in Total Golodirsen Group-8.382 ± 29.4566
SecondaryPart 2b: Percent Change From Baseline in Forced Vital Capacity Predicted (FVC%p) at Week144 in Untreated Group (Non-exon 53 Amenable Participants)

FVC was the total amount of air exhaled during the forced expiratory volume test that was measured during spirometry and is the most important measurement of lung function. This test requires participant to breath into a tube connected to a machine that measures the amount of air that can be moved in and out of the lungs after taking an inhaled bronchodilator medicine which was used to dilate participant bronchial (breathing) tubes. Percent of predicted FVC = (observed value)/ (predicted value) \* 100%.

Time frame:
Baseline, Week 144
Reported as:
Mean · Percent change
Part 2b: Percent Change From Baseline in Forced Vital Capacity Predicted (FVC%p) at Week144 in Untreated Group (Non-exon 53 Amenable Participants)
Percent changePart 2b: Untreated Group (Natural History of Non-exon 53)
Part 2b: Percent Change From Baseline in Forced Vital Capacity Predicted (FVC%p) at Week144 in Untreated Group (Non-exon 53 Amenable Participants)-6.739 ± 17.5278
SecondaryPart 2a: Change From Baseline in Dystrophin Intensity Levels Determined by Immunohistochemistry (IHC) at Week 48 in Total Golodirsen Group

Change from baseline in dystrophin Intensity levels (in muscle biopsy samples) was determined by Immunohistochemistry in total golodirsen group.

Time frame:
Baseline, Week 48
Reported as:
Mean · Percent dystrophin positive fibers
Part 2a: Change From Baseline in Dystrophin Intensity Levels Determined by Immunohistochemistry (IHC) at Week 48 in Total Golodirsen Group
Percent dystrophin positive fibersPart 2a: Total Golodirsen Group
Part 2a: Change From Baseline in Dystrophin Intensity Levels Determined by Immunohistochemistry (IHC) at Week 48 in Total Golodirsen Group0.023 ± 0.0243
SecondaryPart 2a: Percent Change From Baseline in Exon 53 Skipping Determined by Reverse Transcription Polymerase Chain Reaction (PCR) at Week 48 in Total Golodirsen Group

Percent change from baseline in Exon 53 skipping (in muscle biopsy samples) was determined by reverse transcription polymerase chain reaction in total golodirsen group.

Time frame:
Baseline, Week 48
Reported as:
Mean · Percent change
Part 2a: Percent Change From Baseline in Exon 53 Skipping Determined by Reverse Transcription Polymerase Chain Reaction (PCR) at Week 48 in Total Golodirsen Group
Percent changePart 2a: Total Golodirsen Group
Part 2a: Percent Change From Baseline in Exon 53 Skipping Determined by Reverse Transcription Polymerase Chain Reaction (PCR) at Week 48 in Total Golodirsen Group16.363 ± 10.6223
SecondaryPart 2a: Percent Change From Baseline in Dystrophin Positive Fibers Determined by Immunohistochemistry (IHC) at Week 48 in Total Golodirsen Group

Percent change from baseline in dystrophin positive fibers (in muscle biopsy samples) were determined by Immunohistochemistry at Week 48 in total golodirsen group.

Time frame:
Baseline, Week 48
Reported as:
Mean · Percent change
Part 2a: Percent Change From Baseline in Dystrophin Positive Fibers Determined by Immunohistochemistry (IHC) at Week 48 in Total Golodirsen Group
Percent changePart 2a: Total Golodirsen Group
Part 2a: Percent Change From Baseline in Dystrophin Positive Fibers Determined by Immunohistochemistry (IHC) at Week 48 in Total Golodirsen Group12.508 ± 14.6012

Adverse events

Collected over From start of study drug administration up to 189 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Placebo0/4 (0%)0/4 (0%)4/4 (100%)
Part 1: Golodirsen (4 mg/kg)0/8 (0%)0/8 (0%)5/8 (62.5%)
Part 1: Golodirsen (10 mg/kg)0/8 (0%)0/8 (0%)5/8 (62.5%)
Part 1: Golodirsen (20 mg/kg)0/8 (0%)0/8 (0%)3/8 (37.5%)
Part 1: Golodirsen (30 mg/kg)0/8 (0%)0/8 (0%)6/8 (75%)
Part 2a: Total Golodirsen Group0/25 (0%)4/25 (16%)25/25 (100%)
Part 2b: Untreated Group (Natural History of Non-exon 53)0/14 (0%)2/14 (14.3%)10/14 (71.4%)
Most frequent serious events
Most frequent serious events
EventPart 1: PlaceboPart 1: Golodirsen (4 mg/kg)Part 1: Golodirsen (10 mg/kg)Part 1: Golodirsen (20 mg/kg)Part 1: Golodirsen (30 mg/kg)Part 2a: Total Golodirsen GroupPart 2b: Untreated Group (Natural History of Non-exon 53)
Tooth development disorderGastrointestinal disorders0/40/80/80/80/80/251/14
RhabdomyolysisMusculoskeletal and connective tissue disorders0/40/80/80/80/80/251/14
HaematemesisGastrointestinal disorders0/40/80/80/80/81/250/14
VomitingGastrointestinal disorders0/40/80/80/80/81/250/14
PyrexiaGeneral disorders0/40/80/80/80/81/250/14
Gastroenteritis viralInfections and infestations0/40/80/80/80/81/250/14
HypocalcaemiaMetabolism and nutrition disorders0/40/80/80/80/81/250/14
ConvulsionNervous system disorders0/40/80/80/80/81/250/14
Tonsillar hypertrophyRespiratory, thoracic and mediastinal disorders0/40/80/80/80/81/250/14
Most frequent other events
Showing 10 of 105
Most frequent other events
EventPart 1: PlaceboPart 1: Golodirsen (4 mg/kg)Part 1: Golodirsen (10 mg/kg)Part 1: Golodirsen (20 mg/kg)Part 1: Golodirsen (30 mg/kg)Part 2a: Total Golodirsen GroupPart 2b: Untreated Group (Natural History of Non-exon 53)
RhinitisInfections and infestations0/40/80/80/82/816/250/14
CoughRespiratory, thoracic and mediastinal disorders0/40/80/80/83/816/253/14
VomitingGastrointestinal disorders0/40/80/81/81/815/251/14
DiarrhoeaGastrointestinal disorders0/41/80/80/81/814/250/14
NasopharyngitisInfections and infestations1/41/80/80/81/813/254/14
PyrexiaGeneral disorders1/42/81/81/84/813/251/14
Platelet count increasedInvestigations2/40/80/80/80/80/250/14
RhinorrhoeaRespiratory, thoracic and mediastinal disorders0/40/80/80/82/812/250/14
ArthralgiaMusculoskeletal and connective tissue disorders0/40/80/80/81/811/250/14
HeadacheNervous system disorders0/40/80/81/83/811/250/14

Baseline characteristics

Safety set included all randomized participants from Part 1 and all Part 2 participants amenable to exon 53 skipping who received any amount of study drug, and all untreated participants who entered Part 2.

Age, Continuous
Age, Continuous(years)Part 1: PlaceboPart 1: GolodirsenPart 2a: Total Golodirsen GroupPart 2b: Untreated Group (Natural History of Non-exon 53)Total
Part 17.0 ± 0.828.6 ± 2.07——8.1 ± 1.88
Part 2——8.4 ± 2.188.5 ± 1.918.4 ± 2.06
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: PlaceboPart 1: GolodirsenPart 2a: Total Golodirsen GroupPart 2b: Untreated Group (Natural History of Non-exon 53)Total
Part 1 — Female00——0
Part 1 — Male48——12
Part 2 — Female——000
Part 2 — Male——251439
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1: PlaceboPart 1: GolodirsenPart 2a: Total Golodirsen GroupPart 2b: Untreated Group (Natural History of Non-exon 53)Total
Part 1 — Hispanic or Latino11——2
Part 1 — Not Hispanic or Latino14——5
Part 1 — Unknown or Not Reported23——5
Part 2 — Hispanic or Latino——404
Part 2 — Not Hispanic or Latino——9918
Part 2 — Unknown or Not Reported——12517
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1: PlaceboPart 1: GolodirsenPart 2a: Total Golodirsen GroupPart 2b: Untreated Group (Natural History of Non-exon 53)Total
Part 1 — American Indian or Alaska Native00——0
Part 1 — Asian00——0
Part 1 — Native Hawaiian or Other Pacific Islander00——0
Part 1 — Black or African American00——0
Part 1 — White38——11
Part 1 — More than one race10——1
Part 1 — Unknown or Not Reported00——0
Part 2 — American Indian or Alaska Native——000
Part 2 — Asian——011
Part 2 — Native Hawaiian or Other Pacific Islander——000
Part 2 — Black or African American——000
Part 2 — White——231134
Part 2 — More than one race——224
Part 2 — Unknown or Not Reported——000
08

Study locations

5 sites
  • Boston Children's Hospital
    Boston, Massachusetts 02116, United States
  • Institute de Myologie
    Paris, 75013, France
  • Policlinico Universitario A Gemelli
    Rome, 00168, Italy
  • Great Ormond Street Hospital for Children NHS Foundation Trust
    London, WC1N 3JH, United Kingdom
  • Newcastle University Hospital
    Newcastle, United Kingdom
09

References and documents

Publications

  • Frank DE, Schnell FJ, Akana C, El-Husayni SH, Desjardins CA, Morgan J, Charleston JS, Sardone V, Domingos J, Dickson G, Straub V, Guglieri M, Mercuri E, Servais L, Muntoni F; SKIP-NMD Study Group. Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy. Neurology. 2020 May 26;94(21):e2270-e2282. doi: 10.1212/WNL.0000000000009233. Epub 2020 Mar 5. Erratum In: Neurology. 2023 May 9;100(19):936. doi: 10.1212/WNL.0000000000012406. PubMed 32139505 ↗
  • Servais L, Mercuri E, Straub V, Guglieri M, Seferian AM, Scoto M, Leone D, Koenig E, Khan N, Dugar A, Wang X, Han B, Wang D, Muntoni F; SKIP-NMD Study Group. Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-human, Multicenter, Two-Part, Open-Label, Phase 1/2 Trial. Nucleic Acid Ther. 2022 Feb;32(1):29-39. doi: 10.1089/nat.2021.0043. Epub 2021 Nov 17. PubMed 34788571 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2015 to primary completion in Mar 2019, 50 months.

Results were first posted in Oct 2020, 1 year 6 months after primary completion.

Of 23 phase 1/2 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 63. This study's 50 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2014
First posted
Dec 8, 2014
StartActual
Jan 13, 2015
Primary completionActual
Mar 25, 2019
CompletionActual
Mar 25, 2019
Results first posted
Oct 19, 2020
Last update
Oct 19, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 19, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02310906
Collaborators
Institut de Myologie, France, Consultants for Research in Imaging and Spectroscopy, Great Ormond Street Hospital for Children NHS Foundation Trust, Catholic University of the Sacred Heart, Royal Holloway University, SYSNAV, University College, London, University of Newcastle Upon-Tyne
Responsible party
Sponsor
First posted
Dec 8, 2014
Start date
Jan 13, 2015
Primary completion
Mar 25, 2019
Completion
Mar 25, 2019
Results posted
Oct 19, 2020
Last update
Oct 19, 2020

Study contacts

Medical Director
study director · Sarepta Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Golodirsen

Start the discussion